-
Sebastian Giebel Presents at EBMT 2025: How Prior alloHCT Shapes CART19 Outcomes in B-ALL
At EBMT 2025, Professor Sebastian Giebel shared key data from a real-world, multicenter study on CART19 therapy in 345 B-ALL patients. The study highlights how prior alloHCT exposure impacts survival…
-
EBMT 2025 | Dr. maria victoria mateos manteca on MRD as a Surrogate Marker in Myeloma Outcomes
At this year’s EBMT Annual Meeting, Dr. María-Victoria Mateos (Salamanca, Spain) delivered an impactful presentation titled “MRD in Myeloma as Surrogate Marker for Outcomes.”
-
Allogeneic SCT in Follicular Lymphoma: Still a Valid Option in the Modern Therapeutic Landscape
At EBMT 2025, Yasmina Serroukh from Erasmus MC presented a benchmark study evaluating the role of allogeneic stem cell transplantation (allo-SCT) in follicular lymphoma (FL). The analysis, drawn from a…
-
Prof. Heiner Wedemeyer on the Unfinished Mission of HCV Elimination
In a recent editorial published in the Journal of Hepatology (April 2025), Prof. Heiner Wedemeyer (Hannover Medical School) a leading voice in hepatology joined Niklas Luhmann in reflecting on more…
-
Can we truly personalize leukemia-free survival prediction after allo-HCT?
At EBMT 2025, Professor Alexandros Spyridonidis delivered a compelling presentation addressing one of the most pressing challenges in hematopoietic stem cell transplantation: how to provide patients with accurate, individualized prognostic information.
-
Evaluating FMT in Hepatic Encephalopathy: Insights from the THEMATIC Trial
In a recent editorial published in the Journal of Hepatology (March 24, 2025), Professors Debbie Shawcross and Vishal C. Patel spotlight the THEMATIC trial—a phase II RCT investigating the safety…
-
ELCC 2025 | Dr. Benjamin Besse Discusses De-escalation in Lung Cancer Treatment: How Far Are We From the Goal?
At the 2025 European Lung Cancer Conference (ELCC), Professor Benjamin Besse from the Gustave Roussy Institute presented a report titled “Less is More: De-escalation Strategies in Patient Management and Clinical Trials.” He emphasized that while de-escalation strategies for drug treatments are still being actively explored, clinical applications face challenges, such as insufficient research funding.
-
Imaging, Heterogeneity & RCC Recurrence: Prof. Xiongjun Ye Shares Research Highlights at EAU25
At #EAU25, Professor Xiongjun Ye (叶雄俊) from Peking Union Medical College Hospital shared his team’s latest findings on MRI accuracy in renal tumor diagnosis, tumor heterogeneity in RCC, and strategies for managing postoperative recurrence. His group’s EAU-selected research explores how imaging limitations and intratumoral heterogeneity affect treatment outcomes—offering new perspectives for optimizing RCC care.
Connecting Medical Expertise through Media